SPECIALTY GUIDELINE MANAGEMENT

RYDAPT (midostaurin)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered covered benefits provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications

- 1. Rydapt is indicated, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive, as detected by an FDA approved test.
 - *Limitations of Use*: Rydapt is not indicated as a single-agent induction therapy for the treatment of patients with AML.
- Rydapt is indicated for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).

B. Compendial Uses

- 1. AML: Relapsed/refractory disease, post-induction therapy, re-induction of residual disease
- 2. Myeloid/lymphoid neoplasms with eosinophilia and FGFR1 or FLT3 rearrangements in chronic phase
- 3. Myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and FGFR1 or FLT3 rearrangements in blast phase

All other indications are considered experimental/investigational and are not medically necessary.

II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review: Medical record documentation of FLT3 mutation or FGFR1 rearrangement (where applicable)

III. CRITERIA FOR INITIAL APPROVAL

A. Acute myeloid leukemia (AML)

Authorization of 12 months may be granted for the treatment of FLT3 mutation-positive AML when it is not used as a single-agent for induction therapy.

B. Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL)

Rydapt 1817-A SGM P2022

© 2022 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



Reference number
1817-A

Authorization of 12 months may be granted for the treatment of ASM, SM-AHN, or MCL as a single agent.

C. Myeloid/Lymphoid Neoplasms with eosinophilia

Authorization of 12 months may be granted for the treatment of myeloid and/or lymphoid neoplasms with eosinophilia with a FGFR1 or FLT3 rearrangement in the chronic phase or blast phase.

IV. CONTINUATION OF THERAPY


A. Acute myeloid leukemia (AML)

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization when there is no evidence of unacceptable toxicity.


B. Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), mast cell leukemia (MCL), myeloid/lymphoid neoplasms with eosinophilia Authorization of 12 months may be granted for continued treatment in members requesting reauthorization when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

V. REFERENCES

- 1. Rydapt [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2021.
- 2. The NCCN Drugs & Biologics Compendium[®]. © 2022 National Comprehensive Cancer Network, Inc. Available at: https://www.nccn.org. Accessed January 10, 2022.



pharmaceutical manufacturers that are not affiliated with CVS Caremark.



This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of